Winslow Capital Management LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Winslow Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,020,567 shares of the biopharmaceutical company's stock after buying an additional 58,960 shares during the period. Winslow Capital Management LLC owned about 0.79% of Alnylam Pharmaceuticals worth $240,150,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $1,045,822,000. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $577,941,000. Raymond James Financial Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $65,295,000. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $61,160,000. Finally, Proficio Capital Partners LLC increased its position in Alnylam Pharmaceuticals by 25,929.6% in the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after purchasing an additional 192,916 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded down $2.46 on Monday, reaching $235.31. The company's stock had a trading volume of 229,483 shares, compared to its average volume of 862,706. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $30.61 billion, a P/E ratio of -108.44 and a beta of 0.30. The stock's 50 day simple moving average is $253.20 and its two-hundred day simple moving average is $258.26.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ALNY shares. Bank of America raised their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reissued a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Royal Bank of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Finally, Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.